Valuation : Gilead Sciences, Inc.

Market Cap 18TCr 16TCr 15TCr 13TCr 25TCr 17,26700Cr 25TCr 1,74500Cr 67TCr 8,75800Cr 68TCr 66TCr 27,81800Cr P/E 2026 *
-44.1x
P/E 2027 * 18.2x
Enterprise Value 20TCr 17TCr 16TCr 15TCr 27TCr 18,86800Cr 28TCr 1,90700Cr 73TCr 9,57000Cr 74TCr 72TCr 30,39700Cr EV / Sales 2026 *
6.43x
EV / Sales 2027 * 5.81x
Free-Float
99.88%
Yield 2026 *
2.26%
Yield 2027 * 2.3%
1 day-1.96%
1 week-4.24%
Current month-1.05%
1 month+8.83%
3 months+19.20%
6 months-2.52%
Current year+17.98%
1 week 143.67
Extreme 143.67
151.18
1 month 132.01
Extreme 132.01
152.55
Current year 116.88
Extreme 116.88
157.29
1 year 108.46
Extreme 108.4601
157.29
3 years 62.07
Extreme 62.07
157.29
5 years 57.16
Extreme 57.165
157.29
10 years 56.56
Extreme 56.56
157.29
Manager TitleAgeSince
Chief Executive Officer 61 01/03/2019
Director of Finance/CFO 56 01/11/2019
Compliance Officer - 18/12/2025
Director TitleAgeSince
Director/Board Member 58 19/08/2016
Director/Board Member 73 01/01/2018
Director/Board Member 72 09/05/2018
Date Insider Type Main position Quantity % Market Cap. Importance
01/09/26 Sell

Chief Executive Officer

-15,000 0.0012%
26/08/26 Exercice

Director

54,000 0.0043%
20/08/26 Exercice

Director

15,000 0.0012%
Change 5-day change 1-year change 3-year change Capi.($)
-0.58%-4.24%+25.65%+87.97% 18TCr
-0.11%-3.16%+48.82%+88.56% 1,00200Cr
-0.27%-4.34%+51.52%+63.75% 64TCr
+1.63%-2.00%+20.49%+71.10% 44TCr
-0.63%-1.06%+28.11%+34.59% 34TCr
+0.43%-14.61%+9.88%+27.26% 26TCr
+0.93%-1.82%-1.82%+8.41% 24TCr
-2.25%-13.88%+37.33%+46.14% 21TCr
-0.90%-5.09%-15.47%-57.75% 20TCr
-0.47%-4.03%+12.54%-18.53% 16TCr
Average -0.12%-4.92%+21.70%+35.15% 36.88TCr
Weighted average by Cap. +0.10%-4.24%+31.01%+52.49%

Financials

2026 *2027 *
Net sales 3.07TCr 2.64TCr 2.49TCr 2.27TCr 4.24TCr 2,93400Cr 4.28TCr 30TCr 11TCr 1,48800Cr 12TCr 11TCr 4,72700Cr 3.27TCr 2.81TCr 2.65TCr 2.42TCr 4.52TCr 3,12500Cr 4.56TCr 32TCr 12TCr 1,58500Cr 12TCr 12TCr 5,03400Cr
Net income -427.47Cr -367.62Cr -346.86Cr -315.99Cr -590.7Cr -41TCr -596.07Cr -4.13TCr -1.59TCr -21TCr -1.61TCr -1.57TCr -66TCr 1.03TCr 883.65Cr 833.75Cr 759.54Cr 1.42TCr 98TCr 1.43TCr 9.93TCr 3.82TCr 50TCr 3.86TCr 3.77TCr 1,58300Cr
Net Debt 1.67TCr 1.44TCr 1.36TCr 1.24TCr 2.31TCr 1,60100Cr 2.33TCr 16TCr 6.23TCr 81TCr 6.29TCr 6.15TCr 2,57900Cr 912.45Cr 784.71Cr 740.39Cr 674.49Cr 1.26TCr 87TCr 1.27TCr 8.82TCr 3.39TCr 44TCr 3.43TCr 3.35TCr 1,40500Cr
Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.2%): for the treatment of HIV (71.8% of net sales), oncology diseases (11.2%), hepatitis B virus (11.1%), Ebola virus (3.2%) and other (2.7%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.8%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (70.9%), Europe (17.2%) and other (11.9%).
Employees
17,000
Date Price Change Volume
11/26/11 $144.81 -0.58% 56,54,944
09/26/09 $145.65 -0.68% 45,83,213
08/26/08 $146.64 -2.88% 60,80,502
04/26/04 $151.00 -0.15% 61,81,783
03/26/03 $151.22 +1.08% 44,98,099
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
145.65USD
Average target price
158.15USD
Spread / Average Target
+8.58%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GILD Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!